Advertisement

Breast Cancer

Relevant Articles About Research and Clinical Trials in Breast Cancer

Stories to Watch

VIEW ALL

Advertisement

OncWeekly Featured Trials

 

Breast CancerCapecitabineCarboplatinDato-DXdEribulin MesylateNab-paclitaxelPaclitaxelACTIVE_NOT_RECRUITINGArgentinaBelgiumBrazilCanadaChinaFranceGermanyHungaryIndiaItalyJapanKorea, Republic ofMexicoPhilippinesPolandSingaporeSouth AfricaSpainTaiwanThailandTurkeyUnited KingdomUnited States 9NCT05374512Phase 3
A Study of Dato-DXd Versus Investigator’s Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

A Study of Dato-DXd Versus Investigator’s Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

TNBC (Triple Negative Breast Cancer)CapecitabinePembrolizumabSacituzumab Govitecan-hziy (SG)RecruitingUnited States 9NCT05633654Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

Advertisement

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy

VIEW ALL

SELECT ONCOLOGY JOURNAL ARTICLES

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy

Background Lenvatinib plus PD-1 inhibitors and interventional (LPI) therapy have demonstrated promising treatment effects in unresectable hepatocellular carcinoma (HCC). However, biomarkers for predicting the response to LPI therapy remain to be further explored. We aimed to …

Novel insights into paclitaxels role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment

Novel insights into paclitaxels role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment

Background Triple-negative breast cancer (TNBC) poses unique challenges due to its complex nature and the need for more effective treatments. Recent studies showed encouraging outcomes from combining paclitaxel (PTX) with programmed cell death protein-1 (PD-1) blockade …

Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective - a SENTICOL ancillary study

Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective - a SENTICOL ancillary study

Background Cervical cancer’s lymphatic spread primarily begins from the sentinel lymph nodes (SLNs), underlining their pivotal role in disease metastasis. However, these nodes’ immune gene expression profiles and immunoregulation mechanisms have yet to be explored. Methods Our study …